Top

Published in:

01-01-2008 | Hepatic and Pancreatic Tumors

Improved Long-Term Outcome of Surgery for Advanced Colorectal Liver Metastases: Reasons and Implications for Management on the Basis of a Severity Score

Authors: Axel Andres, MD, Pietro E. Majno, MD, FRCS, Philippe Morel, MD, Laura Rubbia-Brandt, MD, PhD, Emiliano Giostra, MD, Pascal Gervaz, MD, Sylvain Terraz, MD, Abdelkarim S. Allal, MD, Arnaud D. Roth, MD, Gilles Mentha, MD

Published in: Annals of Surgical Oncology | Issue 1/2008

Abstract

Background

The outcome of liver resection for colorectal liver metastases (CRLM) appears to be improving despite the fact that surgery is offered to patients with more-severe disease. To quantify this assumption and to understand its causes we analyzed a series of patients on the basis of a standardized severity score and changes in management occurring over the years.

Methods

Patients’ characteristics, operative data, chemotherapies and follow-up were recorded. CRLM severity was quantified according to Fong’s clinical risk score (CRS), modified to take into account the presence of bilateral liver metastases. Three periods were analyzed, in which different indications, surgical strategies and uses of chemotherapy were applied: 1984–1992, 1993–1998, and 1999–2005.

Results

Between January 1984 and December 2005, 210 liver resections were performed in 180 patients (1984–1992, 43 patients; 1993–1998, 42 patients; 1999–2005, 95 patients). CRLM severity increased throughout the time periods, as did the use of neoadjuvant chemotherapies, repeat resections, and multistep procedures. While the disease-free survival did not improve over time, the 1-, 3- and 5-year overall survival rate increased from 85%, 30%, and 23% in the first period, to 88%, 60%, and 34% in the second period, and to 94%, 69%, and 46% in the third period.

Conclusions

Analysis according to the CRS showed that despite the fact that patients had more severe disease, the overall survival improved over the years, mainly thanks to more aggressive treatment of recurrent disease. Management of advanced CRLM should, from the start, take into account the likelihood of secondary procedures.

Poston GJ. Surgical strategies for colorectal liver metastases. Surg Oncol 2004;13:125–36PubMedCrossRef

Fusai G, Davidson BR. Management of colorectal liver metastases. Colorectal Dis 2003;5:2–23PubMedCrossRef

Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg 2006;93:465–74PubMedCrossRef

Weber JC, Bachellier P, Oussoultzoglou E, Jaeck D. Simultaneous resection of colorectal primary tumour and synchronous liver metastases. Br J Surg 2003;90:956–62PubMedCrossRef

Martin R, Paty P, Fong Y, et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg 2003;197:233–412PubMedCrossRef

Chua HK, Sondenaa K, Tsiotos GG, Larson DR, Wolff BG, Nagorney DM. Concurrent vs. staged colectomy and hepatectomy for primary colorectal cancer with synchronous hepatic metastases. Dis Colon Rectum 2004;47:1310–6PubMedCrossRef

Tanaka K, Shimada H, Matsuo K, Nagano Y, Endo I, Sekido H, Togo S. Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases. Surgery 2004;136:650–9PubMedCrossRef

de Santibanes E, Lassalle FB, McCormack L, Pekolj J, Quintana GO, Vaccaro C, Benati M. Simultaneous colorectal and hepatic resections for colorectal cancer: postoperative and longterm outcomes. J Am Coll Surg 2002;195:196–202PubMedCrossRef

Bismuth H, Majno P. Hepatobiliary surgery. J Hepatol 2000;32:208–24PubMedCrossRef

10.

Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224:509–22PubMedCrossRef

11.

Tanaka K, Adam R, Shimada H, Azoulay D, Levi F, Bismuth H. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003;90:963–9PubMedCrossRef

12.

Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004;15:933–9PubMedCrossRef

13.

Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005;16:1311–9PubMedCrossRef

14.

Punt CJ. New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol 2004;15:1453–9PubMedCrossRef

15.

Figueras J, Valls C, Rafecas A, Fabregat J, Ramos E, Jaurrieta E. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 2001;88:980–5PubMedCrossRef

16.

Azoulay D, Raccuia JS, Castaing D. Right portal vein embolization in preparation for major hepatic resection. J Am Coll Surg 1995;181:267–9

17.

Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg 2000;232:777–85PubMedCrossRef

18.

Shimada H, Tanaka K, Matsuo K, Togo S. Treatment for multiple bilobar liver metastases of colorectal cancer. Langenbecks Arch Surg 2006;391:130–42PubMedCrossRef

19.

Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg 2006;93:872–8PubMedCrossRef

20.

Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309–21PubMedCrossRef

21.

Mala T, Bohler G, Mathisen O, Bergan A, Soreide O. Hepatic resection for colorectal metastases: can preoperative scoring predict patient outcome? World J Surg 2002;26:1348–53PubMedCrossRef

22.

Mann CD, Metcalfe MS, Leopardi LN, Maddern GJ. The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Arch Surg 2004;139:1168–72PubMedCrossRef

23.

Parks R, Gonen M, Kemeny N, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 2007;204:753–63PubMedCrossRef

24.

Bismuth H. Surgical anatomy and anatomical surgery of the liver. World J Surg 1982;6:3–9PubMedCrossRef

25.

Seium Y, Stupp R, Ruhstaller T, et al. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. Ann Oncol 2005;16:762–6PubMedCrossRef

26.

Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15:460–6PubMedCrossRef

27.

Fernandez F, Ritter J, Goodwin J, Linehan D, Hawkins W, Strasberg S. Effect of Steatohepatitis associated with Irinotecan or Oxaliplatin pretreatment on resectability of hepatic colorectal metastases. Am Coll Surg 2005;200:845–53CrossRef

28.

Vauthey JN, Pawlik TM, Ribeiro D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24:2065–72PubMedCrossRef

29.

Weitz J, Koch M, Kienle P, et al. Detection of hematogenic tumor cell dissemination in patients undergoing resection of liver metastases of colorectal cancer. Ann Surg 2000;232:66–72PubMedCrossRef

30.

Koch M, Kienle P, Hinz U, et al. Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases. Ann Surg 2005;241:199–205PubMedCrossRef

31.

Koch M, Kienle P, Kastrati D, et al. Pronostic impact of hematogenous tumor cell dissemination in patients with stage II colorectal cancer. Int J Cancer 2006;118:3072–7PubMedCrossRef

32.

Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005;23:4553–60PubMedCrossRef

33.

Adam R, Pascal G, Azoulay D, Tanaka K, Castaing D, Bismuth H. Liver resection for colorectal metastases. The third hepatectomy. Ann Surg 2003;238:871–84PubMedCrossRef

34.

Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000;321:531–5PubMedCrossRef

35.

Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal cancer. Ann Surg 2005;241:715–24PubMedCrossRef

36.

Zorzi D, Mullen JT, Abdalla EK, et al. Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. J Gastrointest Surg 2006;10:86–94PubMedCrossRef

37.

Elias D, Cavalcanti A, Sabourin JC, Pignon JP, Ducreux M, Lasser P. Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. J Surg Oncol 1998;69:88–93PubMedCrossRef

Title: Improved Long-Term Outcome of Surgery for Advanced Colorectal Liver Metastases: Reasons and Implications for Management on the Basis of a Severity Score
Authors: Axel Andres, MD
Pietro E. Majno, MD, FRCS
Philippe Morel, MD
Laura Rubbia-Brandt, MD, PhD
Emiliano Giostra, MD
Pascal Gervaz, MD
Sylvain Terraz, MD
Abdelkarim S. Allal, MD
Arnaud D. Roth, MD
Gilles Mentha, MD
Publication date: 01-01-2008
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 1/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-007-9607-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Improved Long-Term Outcome of Surgery for Advanced Colorectal Liver Metastases: Reasons and Implications for Management on the Basis of a Severity Score

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2008

Is Case Volume the Only Surrogate for Oncologic Surgical Quality?

Lymphadenectomy in Surgical Oncology

Survival and Health Outcomes After Cytoreductive Surgery With Intraperitoneal Hyperthermic Chemotherapy for Disseminated Peritoneal Cancer of Appendiceal Origin

Laparoscopic Resection of Abdominal Neuroblastoma

Treatment Guidelines for Branch Duct Type Intraductal Papillary Mucinous Neoplasms of the Pancreas: When Can We Operate or Observe?

Sentinel Lymph Node Evaluation Does Not Improve Staging Accuracy in Colon Cancer